BrainStorm to Begin ALS Stem Cell Clinical Trial

BrainStorm Cell Therapeutics has received approval from the Israeli Ministry of Health to conduct a phase I/II clinical trial of its proprietary mesenchymal stem cell therapy in ALS patients. Hadassah Medical Center in Israel will collaborate on the trial for safety and efficacy testing of BrainStorm’s stem cell therapy. In a related story, Taubman has donated $300K to Hadassah to support research for ALS stem cell therapies (http://blogs.jta.org/philanthropy/article/2010/10/13/2741264/taubman-gives-hadassah-300000-to-fight-als).

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail